- Systematic review and meta-analysis of 165 randomised trials, including 19,124 adults receiving rocuronium or vecuronium for elective procedures.
- Sugammadex 2 mg/kg was compared with neostigmine 0.05 mg/kg for neuromuscular blockade reversal, though risk of bias across trials was generally unclear or high.
- Sugammadex shortened time to a train-of-four ratio above 0.9 by 10.49 minutes (95% CI -11.90 to -9.08; moderate GRADE) and lowered the risk of at least one adverse event (RR 0.72, 95% CI 0.61 to 0.84).
- The authors conclude sugammadex probably reverses blockade faster with fewer adverse events, including residual blockade, desaturation and bradycardia, though the evidence is rated moderate certainty.
Pharmacology
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Meta-analysis of 25 randomized controlled trials (3344 patients) comparing perioperative ketamine or esketamine with placebo or standard care for postoperative delirium.
- Ketamine (9 trials) and esketamine (16 trials) were compared with control, with subgroup analyses by dose, regimen, surgery type and timing of assessment.
- Both agents reduced postoperative delirium risk: ketamine RR 0.69 (95% CI 0.49-0.98, P = .04) and esketamine RR 0.58 (95% CI 0.36-0.95, P = .03).
- Dizziness risk rose (RR 1.45, 95% CI 1.14-1.84), and trial sequential analysis found the evidence inconclusive, so the authors call for large multicenter RCTs.
- Systematic review and meta-analysis of 14 reports of randomized trials (1,773 participants in the primary synthesis), all conducted in China, in adults undergoing cardiac surgery.
- Compared remimazolam-based with propofol-based general anesthesia for induction and maintenance.
- Remimazolam was associated with fewer trial-defined intraoperative hypotension (OR 0.31; 95% CI 0.20-0.47) and bradycardia events (OR 0.20; 95% CI 0.12-0.34), and shorter mechanical ventilation (MD -1.84 hours; 95% CI -2.34 to -1.35).
- Length of stay did not reach significance (MD -0.48 days; 95% CI -0.99 to 0.02; p = 0.06), major morbidity and mortality could not be pooled, and certainty was very low.
- Systematic review and meta-analysis of 12 randomised trials (n = 739) comparing remimazolam with sevoflurane for general anaesthesia maintenance or deep sedation.
- Remimazolam was compared with sevoflurane, with outcomes covering intraoperative haemodynamic stability and postoperative nausea and vomiting.
- Remimazolam reduced the risk of intraoperative hypotension versus sevoflurane, RR 0.38 (95% CI 0.25 to 0.57; P < 0.001).
- MAP and heart rate differences appeared only at specific time points, and the PONV reduction came from sensitivity analyses, not the primary analysis.